Why Edwards Lifesciences Corp. Shares Soared
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Edwards Lifesciences , a developer of surgical heart valve therapy products, today rocketed higher by as much as 16% after a federal judge in Delaware on Friday granted a preliminary injunction to limit sales of Medtronic's CoreValve system in the U.S. beginning in seven business days.
So what: According to the press release from Edwards Lifesciences, this ruling relates to a federal jury decision four years ago that CoreValue infringed upon Edwards' U.S. Andersen transcatheter aortic valve replacement patent. The judge also decreed that both Edwards and Medtronic should confer to determine in which instances CoreValve can still be used. As should come as no surprise, Medtronic plans to appeal the court's decision. In response to the late-Friday ruling, JPMorgan Chase upgraded Edwards to neutral from underweight and lifted its price target to $78 from $60. The bank also downgraded Medtronic to neutral and lowered its price target to $64.
Now what: This is certainly positive news for Edwards Lifesciences shareholders considering that the company's top-line growth has been stuck around 5% for some time now, and it could lead to increased sales of Edwards' Sapien valves. Of course, shareholders of either company will want to keep in mind that this is merely an injunction within the U.S., so CoreValve system sales won't be affected in foreign markets. With regard to valuation, given that aforementioned middling growth rate, Edwards' forward P/E of 24 might be a bit excessive even with an aging baby boomer population. For now I'm perfectly happy remaining on the sidelines and watching this situation play out.
Edwards Lifescience shares are soaring today, but even it could have a hard time keeping pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article Why Edwards Lifesciences Corp. Shares Soared originally appeared on Fool.com.Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of JPMorgan Chase and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.